Lung volume reduction surgery is safe and leads to functional improvement in patients who fail or cannot undergo bronchoscopic lung volume reduction

Background: Bronchoscopic lung volume reduction (BLVR) has supplanted surgery in the treatment of patients with advanced emphysema, but not all patients qualify for it. Our study aimed to investigate the outcomes of lung volume reduction surgery (LVRS) among patients who either failed BLVR or were not candidates for it. Methods: We conducted a retrospective analysis of patients who underwent LVRS for upper lobe-predominant - predominant emphysema at a single tertiary center between March 2018 and December 2022. The main outcomes measures were preoperative and postoperative respiratory parameters, perioperative morbidity, and mortality. Results: A total of 67 LVRS recipients were evaluated, including 10 who had failed prior valve placement. The median patient age was 69 years, and 35 (52%) % ) were male. All procedures were performed thoracoscopically, with 36 patients (53.7%) % ) undergoing bilateral LVRS. The median hospital length of stay was 7 days (interquartile range, 6-11 days). Prolonged air leak (>7 > 7 days) occurred in 20 patients. There was one 90-day mortality from a nosocomial pneumonia (non-COVID-related) - COVID-related) and no further deaths at 12 months. There were mean improvements of 10.07% % in forced expiratory volume in 1 second and 4.74% % in diffusing capacity of the lung for carbon monoxide, along with a mean decrease 49.2% % in residual volume (P P < .001 for all). The modified fi ed Medical Research Council dyspnea scale was improved by 1.84 points (P P < .001). Conclusions: LVRS can be performed safely in patients who are not candidates for BLVR and those who fail BLVR and leads to significant fi cant functional improvement. Long-term follow-up is necessary to ensure the sustainability of LVRS benefits fi ts in this patient population. (JTCVS Open 2024;18:369-75)